Step 1 topics → Immunology → Biologic Immunosuppressants and Monoclonal Antibodies

Biologic Immunosuppressants and Monoclonal Antibodies

USMLE Step 1 trap: Confuses basiliximab (IL-2R blocker) with ATG (T-cell depleting agent). ATG depletes T cells via complement-mediated lysis and opsonization, while basiliximab is an anti-CD25 antibody that blocks IL-2 receptor signaling without depleting T cells.

Biologic immunosuppressants are a high-yield category on USMLE Step 1 because the exam expects you to know not just drug names, but specific molecular targets and the clinical consequences of blocking them. This topic spans transplant induction (basiliximab, ATG), autoimmune disease management (TNF inhibitors, tocilizumab, abatacept), and B-cell depletion (rituximab) — and the exam will mix these contexts to see if you can keep the mechanisms straight. The key framework is always: what cell or molecule does this drug target, and what happens when that signal is blocked or that cell is eliminated?

USMLE Step 1 tests this from three main angles. First, recall-based questions ask you to match a drug to its target (e.g., which monoclonal antibody targets CD20). Second, application questions give you a clinical scenario — a transplant patient needing induction, or a rheumatoid arthritis patient about to start a biologic — and ask what must be done first or which drug fits. Third, passage-based questions may describe a mechanism (e.g., 'a fusion protein that binds CD80 and CD86') and ask you to identify the drug or predict its effect on T-cell activation. The mechanistic angle is where most students lose points.

The biggest traps here are conflating drugs that sound similar or are used for similar indications. Students routinely assume basiliximab depletes T cells like ATG does — it doesn't, it just blocks IL-2 signaling. Others assume rituximab targets T cells because it's an immunosuppressant — it targets CD20 on B cells exclusively. And abatacept gets confused with tocilizumab because both are used in RA, but one blocks co-stimulation upstream of T-cell activation while the other blocks a cytokine receptor downstream. Knowing these distinctions cold is what separates a 230 from a 210 on this topic.

From real student decks
84%have cards covering this topic
70%have mature cards
1median lapses in 14 days

Common misconceptions

Common mistake
Wrong: Basiliximab and anti-thymocyte globulin (ATG) both deplete T cells.
Right: ATG depletes T cells via complement-mediated lysis and opsonization, while basiliximab is an anti-CD25 antibody that blocks IL-2 receptor signaling without depleting T cells.
ATG (anti-thymocyte globulin) is a polyclonal antibody that physically eliminates T cells from circulation through complement-mediated lysis and Fc-receptor-mediated opsonization — it's used for induction or acute rejection because it gives you fast, deep T-cell depletion. Basiliximab does something fundamentally different: it's a monoclonal antibody against CD25, the alpha subunit of the IL-2 receptor, so it blocks IL-2 signaling and prevents T-cell clonal expansion without killing any T cells. The distinction matters clinically and mechanistically — don't let shared indications (transplant immunosuppression) fool you into thinking the mechanisms are equivalent.
Common mistake
Gap: Misses the requirement for latent TB screening before initiating TNF inhibitor therapy
TNF inhibitors reactivate latent tuberculosis by impairing granuloma maintenance, so all patients must be screened with PPD or IGRA and treated for latent TB before starting therapy.
TNF-alpha is not just a pro-inflammatory cytokine — it is structurally essential for forming and maintaining the granulomas that contain latent Mycobacterium tuberculosis. When you block TNF with agents like infliximab, adalimumab, or etanercept, existing granulomas break down and latent TB can reactivate into active, disseminated disease. This is why USMLE Step 1 expects you to know that screening with PPD or IGRA is mandatory before initiating any TNF inhibitor, and patients with positive results must complete a course of isoniazid (or equivalent) before starting therapy.
Common mistake
Wrong: Rituximab targets T cells because it is used as an immunosuppressant.
Right: Rituximab is an anti-CD20 monoclonal antibody that depletes B cells and is used in B-cell lymphomas, RA, and antibody-mediated conditions.
It's intuitive to assume that an immunosuppressant must target T cells since T cells are the central coordinators of adaptive immunity — but rituximab is specifically anti-CD20, a surface marker expressed on B cells (from pre-B cell through mature B cell stage, but not plasma cells). This makes rituximab the go-to drug for B-cell lymphomas, B-cell-driven autoimmune conditions like RA and pemphigus vulgaris, and antibody-mediated transplant rejection. Remembering 'ritu-B-mab' as a mnemonic can help anchor this: rituximab = B-cell depletion.
Common mistake
Wrong: Abatacept blocks cytokine signaling like tocilizumab.
Right: Abatacept is a CTLA-4-Ig fusion protein that blocks CD80/86 on APCs, preventing CD28 co-stimulation of T cells, while tocilizumab blocks the IL-6 receptor.
Abatacept and tocilizumab are both used in RA, but they intervene at completely different steps of the immune response. Abatacept is a CTLA-4-Ig fusion protein that mimics the inhibitory signal CTLA-4 delivers to APCs — it binds CD80/CD86 on antigen-presenting cells, competitively blocking the CD28 co-stimulatory signal that T cells need for full activation. Without that second signal, T cells become anergic rather than activated. Tocilizumab, by contrast, acts downstream: it blocks the IL-6 receptor, dampening cytokine-driven inflammation after T cells are already activated. These are two distinct checkpoints — co-stimulation versus cytokine signaling — and the exam expects you to know which drug hits which.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Identify the specific cellular targets of transplant induction agents: ATG depletes T cells through complement and opsonization, while basiliximab blocks the IL-2 receptor (CD25) to suppress T-cell proliferation without depleting them.
  2. Apply knowledge of TNF inhibitor indications — including RA, Crohn's disease, psoriasis, and ankylosing spondylitis — and recognize that all patients must be screened for latent TB (PPD or IGRA) and treated before starting therapy, because TNF is required to maintain granuloma integrity.
  3. Match each biologic to its molecular target: rituximab → CD20 (B cells); abatacept → CD80/CD86 on APCs (blocks CD28 co-stimulation); tocilizumab → IL-6 receptor; eculizumab → complement protein C5.

Can you avoid these mistakes?

A 45-year-old patient with newly diagnosed rheumatoid arthritis is about to start infliximab. Her PPD test shows 12mm of induration. She has no respiratory symptoms and a clear chest X-ray. What must happen before she starts infliximab, and why?
During transplant induction, a physician uses an agent described as 'a polyclonal antibody that causes T-cell lymphopenia within hours of administration.' A second agent used for maintenance is described as 'a monoclonal antibody that prevents T-cell proliferation by blocking IL-2 receptor signaling.' Identify both agents and explain the mechanistic difference.
A patient with a B-cell lymphoma is being treated with a monoclonal antibody that targets a surface marker expressed on B cells but not on plasma cells. Name the antibody, its target, and two non-oncologic conditions for which it is also used.
You are given two drugs used in rheumatoid arthritis: one is a CTLA-4-Ig fusion protein, and the other blocks the IL-6 receptor. For each drug, describe the specific step in T-cell activation it interferes with and name the drug.

Related topics

T Cell Activation and Costimulation Thymus and T Cell Maturation Spleen Architecture and Function Lymph Node and MALT Architecture Innate Immune Cells Overview

See how your Anki deck covers this topic.

Upload your deck for a free audit →